Standard BioTools faces two shareholder lawsuits over Treeline merger disclosures
LAB•Standard BioTools faces two New York shareholder lawsuits alleging omissions in disclosures for its planned merger with Treeline Biosciences. The company also received 15 shareholder demand letters, voluntarily supplemented its disclosures, and denies the allegations.




